Sydney-based Benitec Biopharma Ltd. said June 4 that it completed its previously announced entitlement offer.
The offer allowed existing shareholders to buy 1 new share of the company at 17 Australian cents each for every 2 existing shares held as of May 3.
A total of 36,442,672 new shares were issued under the entitlement offer. The shares are expected to commence trading on the Australian Securities Exchange on June 5.
Benitec develops and sells treatments for chronic and life-threatening illnesses using its gene-silencing therapy.
